Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a
provider of innovative spine surgery solutions dedicated to
revolutionizing the approach to spine surgery, today announced
financial results for the quarter ended September 30, 2019, and
recent corporate highlights.
Third Quarter 2019 Financial
Results
- Total net revenue of $29.2 million; U.S. revenue
of $28.1 million, up 34% compared to the prior year and up 8%
sequentially;
- U.S. gross margin of 70.8%; and
- Cash and cash equivalents of $57.8 million as
of September 30, 2019.
Third Quarter-to-Date Corporate
Highlights
- Closed a follow-on equity offering that generated $54 million
in net proceeds for growth-related investment and expanded the
institutional shareholder base;
- Enhanced clinical distinction with five new product launches:
the IdentiTi™ TLIF Porous Oblique System, the
IdentiTi™ LIF Systems, the AMP™ Anti-Migration LIF Plate
System, the Transcend™ Lateral Interbody Spacer, and the
Trestle Luxe® II Anterior Cervical Plate System;
- Increased contribution from new products to 42% of U.S.
revenue;
- Expanded percentage of U.S. revenue driven by strategic
distribution network to 89%;
- Increased U.S. revenue per case by 17% compared to the prior
year; and
- Expanded senior leadership team by appointing Eric Dasso as
Executive Vice President, Adjunctive Technologies.
“Our continued focus on compelling surgeon
adoption by creating clinical distinction and revitalizing the ATEC
sales channel substantially accelerated organic U.S. revenue growth
in the third quarter,” said Pat Miles, Chairman and Chief Executive
Officer. “As a result, we are increasing 2019 revenue
expectations for the second time this year, now anticipating
full-year U.S. revenue growth of over 26%. I’m proud of all that
our teams have accomplished to date, and I am even more
enthusiastic about the future for spine’s new Organic Innovation
Machine.”
Comparison
of Selected GAAP and Non-GAAP Financial Results for the
Third Quarter 2019 to Third Quarter 2018 |
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Change |
|
September 30, 2019 |
|
September 30, 2018 |
|
$ |
|
% |
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from U.S. products |
$ |
28,051 |
|
|
$ |
20,996 |
|
|
$ |
7,055 |
|
|
34 |
% |
Gross profit
from U.S. products |
|
19,853 |
|
|
|
16,001 |
|
|
|
3,852 |
|
|
24 |
% |
Gross margin
from U.S. products |
|
70.8 |
% |
|
|
76.2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Operating
Expenses |
|
|
|
|
|
|
|
Research and development |
$ |
3,962 |
|
|
$ |
3,157 |
|
|
$ |
805 |
|
|
25 |
% |
Sales, general and administrative |
|
26,792 |
|
|
|
18,833 |
|
|
|
7,959 |
|
|
42 |
% |
Litigation-related expenses |
|
604 |
|
|
|
1,329 |
|
|
|
(725 |
) |
|
(55 |
%) |
Amortization of intangible assets |
|
172 |
|
|
|
187 |
|
|
|
(15 |
) |
|
(8 |
%) |
Transaction-related expenses |
|
- |
|
|
|
66 |
|
|
|
(66 |
) |
|
(100 |
%) |
Restructuring |
|
- |
|
|
|
167 |
|
|
|
(167 |
) |
|
(100 |
%) |
Total operating expenses |
$ |
31,530 |
|
|
$ |
23,739 |
|
|
$ |
7,791 |
|
|
33 |
% |
|
|
|
|
|
|
|
|
Operating
loss |
$ |
(11,597 |
) |
|
$ |
(7,533 |
) |
|
$ |
(4,064 |
) |
|
54 |
% |
|
|
|
|
|
|
|
|
Non-GAAP
operating loss |
$ |
(5,114 |
) |
|
$ |
(3,006 |
) |
|
$ |
(2,108 |
) |
|
70 |
% |
|
|
|
|
|
|
|
|
Non-GAAP
adjusted EBITDA |
$ |
(3,190 |
) |
|
$ |
(1,415 |
) |
|
$ |
(1,775 |
) |
|
125 |
% |
|
|
|
|
|
|
|
|
Revenue from U.S. products for the third quarter 2019 was $28.1
million, up 34% compared to $21.0 million in the third quarter
2018. Revenue growth generated by new products and the strategic
distribution channel continues to outpace the ongoing revenue
impacts of transitioning or discontinuing non-strategic distributor
relationships.
Gross profit and gross margin from U.S. products
for the third quarter 2019 were $19.9 million and 70.8%,
respectively, compared to $16.0 million and 76.2%, respectively,
for the third quarter 2018. U.S. gross margin was impacted by
increased non-cash excess and obsolete write-offs related to legacy
products. On a non-GAAP basis, excluding non-cash excess and
obsolete charges, U.S. gross margin was 78.9% in the third quarter
of 2019, compared to 79.8% in the third quarter of 2018.
Total operating expenses for the third quarter
2019 were $31.5 million compared to $23.7 million in the third
quarter 2018. On a non-GAAP basis, excluding stock-based
compensation, fair value adjustments, litigation-related expenses,
restructuring and transaction-related expenses, total operating
expenses increased to $27.4 million from $20.0 million in 2018,
reflecting increased selling costs from U.S. revenue growth, as
well as increased investments in organic product development to
support new product launches.
Non-GAAP adjusted operating loss, which excludes
stock-based compensation, fair value adjustments,
litigation-related expenses, restructuring, transaction-related
expenses and excess and obsolescence charges, was $5.1 million for
the third quarter 2019, compared to a loss of $3.0 million for the
third quarter 2018.
Non-GAAP adjusted EBITDA, which excludes
stock-based compensation, fair value adjustments,
litigation-related expenses, restructuring, transaction-related
expenses and excess and obsolescence charges in the third quarter
2019 was a loss of $3.2 million, compared to a loss of $1.4 million
in the third quarter 2018.
For more detailed information on non-GAAP
operating expenses, non-GAAP adjusted operating loss and non-GAAP
adjusted EBITDA, please refer to the table, “Alphatec Holdings,
Inc. Reconciliation of Non-GAAP Financial Measures,” that
follows.
Current and long-term debt at face value
includes $45 million in term debt and $11.6 million outstanding
under the Company’s revolving credit facility at September 30,
2019, with cash and cash equivalents of $57.8 million.
Updated 2019 Financial
Outlook
Full Year 2019 |
Previous |
Updated |
|
Guidance ($M) |
YoY Growth |
Guidance ($M) |
YoY Growth |
U.S. Product Revenue |
$100 to $104 |
20% to 24% |
$105 to $107 |
26% to 28% |
International Supply Agreement |
$4 to $5 |
(38%) to (50%) |
No change |
No change |
Total Revenue |
$104 to $109 |
13% to 19% |
$109 to $112 |
19% to 22% |
Investor Conference Call
ATEC will present the results via a live webcast
today at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. At
that time, please click here to access the live webcast. An
audiocast of the presentation will be also be available
domestically at (877) 556-5251 and internationally at (720)
545-0036. The conference ID number is 6098197.
Non-GAAP Financial
Information
To supplement the Company’s financial statements
presented in accordance with U.S. generally accepted accounting
principles (GAAP), the Company reports certain non-GAAP financial
measures, including non-GAAP U.S. gross margin, non-GAAP operating
expenses, non-GAAP operating loss, and non-GAAP Adjusted
EBITDA. The Company believes that these non-GAAP financial
measures provide investors with an additional tool for evaluating
the Company's core performance, which management uses in its own
evaluation of continuing operating performance, and a baseline for
assessing the future earnings potential of the Company. The
Company’s non-GAAP financial measures may not provide information
that is directly comparable to that provided by other companies in
the Company’s industry, as other companies in the industry may
calculate non-GAAP financial results differently, particularly
related to non-recurring, unusual items. Non-GAAP financial results
should be considered in addition to, and not as a substitute for,
or superior to, financial measures calculated in accordance with
GAAP. Included below are reconciliations of the non-GAAP financial
measures to the comparable GAAP financial measures.
About Alphatec Holdings,
Inc.
Alphatec Holdings, Inc., through its
wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp
Surgical, Inc., is a provider of innovative spine surgery solutions
dedicated to revolutionizing the approach to spine surgery. ATEC
designs, develops and markets technology for the treatment of
spinal disorders. The Company markets its products in the
U.S. via independent sales agents and a direct sales force.
Additional information can be found at www.atecspine.com.
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve risks and uncertainty. Such
statements are based on management's current expectations and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. The Company cautions investors that
there can be no assurance that actual results or business
conditions will not differ materially from those projected or
suggested in such forward-looking statements as a result of various
factors. Forward-looking statements include the references to the
Company’s revenue and growth outlook, planned commercial launches
and product introductions, the Company’s strategy in significantly
repositioning the ATEC brand, turning the Company into a growth
organization, creating future market disruption, and the Company’s
future ability to finance its operations. The important
factors that could cause actual operating results to differ
significantly from those expressed or implied by such
forward-looking statements include, but are not limited to: the
uncertainty of success in developing new products or products
currently in the Company’s pipeline; the uncertainties in the
Company’s ability to execute upon its strategic operating plan; the
uncertainties regarding the ability to successfully license or
acquire new products, and the commercial success of such products;
failure to achieve acceptance of the Company’s products by the
surgeon community; failure to obtain FDA or other
regulatory clearance or approval for new products, or unexpected or
prolonged delays in the process; continuation of favorable third
party reimbursement for procedures performed using the Company’s
products; unanticipated expenses or liabilities or other adverse
events affecting cash flow or the Company’s ability to successfully
control its costs or achieve profitability; uncertainty of
additional funding; the Company’s ability to compete with other
products and with emerging new technologies; product liability
exposure; an unsuccessful outcome in any litigation in which the
Company is a defendant; patent infringement claims; claims related
to the Company’s intellectual property and the Company’s ability to
meet its financial obligations under its credit agreements and
the Orthotec LLC settlement agreement. The words “believe,”
“will,” “should,” “expect,” “intend,” “estimate,” “look forward”
and “anticipate,” variations of such words and similar expressions
identify forward-looking statements, but their absence does not
mean that a statement is not a forward-looking statement. A
further list and description of these and other factors, risks and
uncertainties can be found in the Company's most recent annual
report, and any subsequent quarterly and current reports, filed
with the Securities and Exchange Commission. ATEC disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, unless required by law.
Investor/Media Contact: |
|
Company Contact: |
|
|
|
Josh Berg |
|
Jeff Black |
Investor Relations |
|
Chief Financial Officer |
(760) 494-6790 |
|
ir@atecspine.com |
ir@atecspine.com |
|
|
ALPHATEC
HOLDINGS, INC. |
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS |
(in
thousands, except per share amounts - unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months
Ended |
|
September 30, |
|
September 30, |
|
|
2019 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2018 |
|
|
|
|
|
|
|
|
|
Revenues: |
|
|
|
|
|
|
|
Revenue from U.S. products |
$ |
28,051 |
|
|
$ |
20,996 |
|
|
$ |
77,099 |
|
|
$ |
60,606 |
|
Revenue from international supply agreement |
|
1,150 |
|
|
|
2,006 |
|
|
|
3,976 |
|
|
|
5,745 |
|
Total revenues |
|
29,201 |
|
|
|
23,002 |
|
|
|
81,075 |
|
|
|
66,351 |
|
Cost of
revenues |
|
9,268 |
|
|
|
6,796 |
|
|
|
25,688 |
|
|
|
19,686 |
|
Gross
profit |
|
19,933 |
|
|
|
16,206 |
|
|
|
55,387 |
|
|
|
46,665 |
|
|
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
Research and development |
|
3,962 |
|
|
|
3,157 |
|
|
|
10,791 |
|
|
|
6,952 |
|
Sales, general and administrative |
|
26,792 |
|
|
|
18,833 |
|
|
|
72,360 |
|
|
|
53,628 |
|
Litigation-related expenses |
|
604 |
|
|
|
1,329 |
|
|
|
4,427 |
|
|
|
4,143 |
|
Amortization of intangible assets |
|
172 |
|
|
|
187 |
|
|
|
526 |
|
|
|
551 |
|
Transaction-related expenses |
|
- |
|
|
|
66 |
|
|
|
- |
|
|
|
1,546 |
|
Gain on settlement |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(6,168 |
) |
Restructuring expenses |
|
- |
|
|
|
167 |
|
|
|
60 |
|
|
|
758 |
|
Total
operating expenses |
|
31,530 |
|
|
|
23,739 |
|
|
|
88,164 |
|
|
|
61,410 |
|
Operating
loss |
|
(11,597 |
) |
|
|
(7,533 |
) |
|
|
(32,777 |
) |
|
|
(14,745 |
) |
Total other expenses, net |
|
(2,926 |
) |
|
|
(1,754 |
) |
|
|
(6,966 |
) |
|
|
(5,183 |
) |
Loss from
continuing operations before taxes |
|
(14,523 |
) |
|
|
(9,287 |
) |
|
|
(39,743 |
) |
|
|
(19,928 |
) |
Income tax (benefit) provision |
|
20 |
|
|
|
26 |
|
|
|
122 |
|
|
|
(1,697 |
) |
Loss from
continuing operations |
|
(14,543 |
) |
|
|
(9,313 |
) |
|
|
(39,865 |
) |
|
|
(18,231 |
) |
Loss from discontinued operations |
|
(24 |
) |
|
|
(42 |
) |
|
|
(106 |
) |
|
|
(116 |
) |
Net
loss |
$ |
(14,567 |
) |
|
$ |
(9,355 |
) |
|
$ |
(39,971 |
) |
|
$ |
(18,347 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss per share, basic and diluted: |
|
|
|
|
|
|
|
Continuing operations |
$ |
(0.26 |
) |
|
$ |
(0.22 |
) |
|
$ |
(0.81 |
) |
|
$ |
(0.56 |
) |
Discontinued operations |
|
(0.00 |
) |
|
|
(0.00 |
) |
|
|
(0.00 |
) |
|
|
(0.00 |
) |
Net loss per
share, basic and diluted |
$ |
(0.26 |
) |
|
$ |
(0.22 |
) |
|
$ |
(0.81 |
) |
|
$ |
(0.56 |
) |
|
|
|
|
|
|
|
|
Shares used
in calculating basic and diluted net loss per share |
|
55,736 |
|
|
|
42,497 |
|
|
|
49,252 |
|
|
|
32,658 |
|
|
|
|
|
|
|
|
|
Stock-based compensation included in: |
|
|
|
|
|
|
|
Cost of
revenue |
$ |
57 |
|
|
$ |
18 |
|
|
$ |
113 |
|
|
$ |
51 |
|
Research and
development |
|
388 |
|
|
|
179 |
|
|
|
921 |
|
|
|
192 |
|
Sales,
general and administrative |
|
3,158 |
|
|
|
1,478 |
|
|
|
6,532 |
|
|
|
3,199 |
|
|
$ |
3,603 |
|
|
$ |
1,675 |
|
|
$ |
7,566 |
|
|
$ |
3,442 |
|
|
|
|
|
|
|
|
|
ALPHATEC
HOLDINGS, INC. |
CONDENSED
CONSOLIDATED BALANCE SHEETS |
(in
thousands) |
|
|
|
|
|
|
|
|
|
September
30, |
|
December
31, |
|
2019 |
|
2018 |
|
(Unaudited) |
|
|
ASSETS |
Current
assets: |
|
|
|
Cash |
$ |
57,843 |
|
$ |
29,054 |
Accounts receivable, net |
|
15,430 |
|
|
15,095 |
Inventories, net |
|
33,065 |
|
|
28,765 |
Prepaid expenses and other current assets |
|
10,852 |
|
|
2,380 |
Current assets of discontinued operations |
|
214 |
|
|
242 |
Total
current assets |
|
117,404 |
|
|
75,536 |
|
|
|
|
Property and
equipment, net |
|
18,723 |
|
|
13,235 |
Right-of-use
asset |
|
2,112 |
|
|
- |
Goodwill |
|
13,897 |
|
|
13,897 |
Intangibles,
net |
|
25,882 |
|
|
26,408 |
Other
assets |
|
214 |
|
|
347 |
Noncurrent
assets of discontinued operations |
|
51 |
|
|
54 |
Total
assets |
$ |
178,283 |
|
$ |
129,477 |
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' EQUITY |
Current
liabilities: |
|
|
|
Accounts payable |
$ |
6,010 |
|
$ |
4,399 |
Accrued expenses |
|
22,972 |
|
|
22,316 |
Current portion of long-term debt |
|
836 |
|
|
3,276 |
Current portion of lease liability |
|
1,263 |
|
|
- |
Current liabilities of discontinued operations |
|
504 |
|
|
621 |
Total
current liabilities |
|
31,585 |
|
|
30,612 |
|
|
|
|
Total long
term liabilities |
|
65,441 |
|
|
57,688 |
|
|
|
|
Redeemable
preferred stock |
|
23,603 |
|
|
23,603 |
Stockholders' equity |
|
57,654 |
|
|
17,574 |
Total
liabilities and stockholders' equity |
$ |
178,283 |
|
$ |
129,477 |
|
|
|
|
ALPHATEC
HOLDINGS, INC. |
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES |
(in
thousands - unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months
Ended |
|
September 30, |
|
September 30, |
|
|
2019 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses |
|
31,530 |
|
|
|
23,739 |
|
|
|
88,164 |
|
|
|
61,410 |
|
Adjustments: |
|
|
|
|
|
|
|
Stock-based compensation |
|
(3,546 |
) |
|
|
(1,657 |
) |
|
|
(7,453 |
) |
|
|
(3,391 |
) |
Contingent consideration fair value adjustment |
|
- |
|
|
|
(546 |
) |
|
|
(289 |
) |
|
|
(646 |
) |
Litigation-related expenses |
|
(604 |
) |
|
|
(1,329 |
) |
|
|
(4,427 |
) |
|
|
(4,143 |
) |
Restructuring |
|
- |
|
|
|
(167 |
) |
|
|
(60 |
) |
|
|
(758 |
) |
Transaction-related expenses |
|
- |
|
|
|
(66 |
) |
|
|
- |
|
|
|
(1,546 |
) |
Gain on settlement |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
6,168 |
|
Non-GAAP
operating expenses |
$ |
27,380 |
|
|
$ |
19,974 |
|
|
$ |
75,935 |
|
|
$ |
57,094 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months
Ended |
|
September 30, |
|
September 30, |
|
|
2019 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2018 |
|
|
|
|
|
|
|
|
|
Operating
loss, as reported |
$ |
(11,597 |
) |
|
$ |
(7,533 |
) |
|
$ |
(32,777 |
) |
|
$ |
(14,745 |
) |
Add back
significant items: |
|
|
|
|
|
|
|
Stock-based compensation |
|
3,603 |
|
|
|
1,675 |
|
|
|
7,566 |
|
|
|
3,442 |
|
Contingent consideration fair value adjustment |
|
- |
|
|
|
546 |
|
|
|
289 |
|
|
|
646 |
|
Litigation-related expenses |
|
604 |
|
|
|
1,329 |
|
|
|
4,427 |
|
|
|
4,143 |
|
Restructuring |
|
- |
|
|
|
167 |
|
|
|
60 |
|
|
|
758 |
|
Transaction-related expenses |
|
- |
|
|
|
66 |
|
|
|
- |
|
|
|
1,546 |
|
Excess & obsolete charges |
|
2,276 |
|
|
|
744 |
|
|
|
6,451 |
|
|
|
2,016 |
|
Gain on settlement |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(6,168 |
) |
Adjusted
operating loss |
|
(5,114 |
) |
|
|
(3,006 |
) |
|
|
(13,984 |
) |
|
|
(8,362 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
loss, as reported |
$ |
(11,597 |
) |
|
$ |
(7,533 |
) |
|
$ |
(32,777 |
) |
|
$ |
(14,745 |
) |
Depreciation |
|
1,752 |
|
|
|
1,405 |
|
|
|
4,828 |
|
|
|
4,454 |
|
Amortization of intangible assets |
|
172 |
|
|
|
186 |
|
|
|
526 |
|
|
|
612 |
|
EBITDA |
|
(9,673 |
) |
|
|
(5,942 |
) |
|
|
(27,423 |
) |
|
|
(9,679 |
) |
Add back
significant items: |
|
|
|
|
|
|
|
Stock-based compensation |
|
3,603 |
|
|
|
1,675 |
|
|
|
7,566 |
|
|
|
3,442 |
|
Contingent consideration fair value adjustment |
|
- |
|
|
|
546 |
|
|
|
289 |
|
|
|
646 |
|
Litigation-related expenses |
|
604 |
|
|
|
1,329 |
|
|
|
4,427 |
|
|
|
4,143 |
|
Restructuring |
|
- |
|
|
|
167 |
|
|
|
60 |
|
|
|
758 |
|
Transaction-related expenses |
|
- |
|
|
|
66 |
|
|
|
- |
|
|
|
1,546 |
|
Excess & obsolete charges |
|
2,276 |
|
|
|
744 |
|
|
|
6,451 |
|
|
|
2,016 |
|
Gain on settlement |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(6,168 |
) |
Adjusted
EBITDA |
$ |
(3,190 |
) |
|
$ |
(1,415 |
) |
|
$ |
(8,630 |
) |
|
$ |
(3,296 |
) |
|
|
|
|
|
|
|
|
ALPHATEC
HOLDINGS, INC. |
RECONCILIATION OF GEOGRAPHIC SEGMENT REVENUES AND GROSS
PROFIT |
(in
thousands, except percentages - unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months
Ended |
|
September 30, |
|
September 30, |
|
|
2019 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2018 |
|
Revenues by
source |
|
|
|
|
|
|
|
Revenue from
U.S. products |
$ |
28,051 |
|
|
$ |
20,996 |
|
|
$ |
77,099 |
|
|
$ |
60,606 |
|
Revenue from
international supply agreement |
|
1,150 |
|
|
|
2,006 |
|
|
|
3,976 |
|
|
|
5,745 |
|
Total
revenues |
$ |
29,201 |
|
|
$ |
23,002 |
|
|
$ |
81,075 |
|
|
$ |
66,351 |
|
|
|
|
|
|
|
|
|
Gross profit
by source |
|
|
|
|
|
|
|
Revenue from
U.S. products |
$ |
19,853 |
|
|
$ |
16,001 |
|
|
$ |
55,087 |
|
|
$ |
46,230 |
|
Revenue from
international supply agreement |
|
80 |
|
|
|
205 |
|
|
|
300 |
|
|
|
435 |
|
Total gross
profit |
$ |
19,933 |
|
|
$ |
16,206 |
|
|
$ |
55,387 |
|
|
$ |
46,665 |
|
|
|
|
|
|
|
|
|
Gross profit
margin by source |
|
|
|
|
|
|
|
Revenue from
U.S. products |
|
70.8 |
% |
|
|
76.2 |
% |
|
|
71.4 |
% |
|
|
76.3 |
% |
Revenue from
international supply agreement |
|
7.0 |
% |
|
|
10.2 |
% |
|
|
7.5 |
% |
|
|
7.6 |
% |
Total gross
profit margin |
|
68.3 |
% |
|
|
70.5 |
% |
|
|
68.3 |
% |
|
|
70.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RECONCILIATION OF GAAP TO NON-GAAP GROSS PROFIT AND GROSS
MARGIN FROM U.S. PRODUCTS |
(in
thousands, except percentages - unaudited) |
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months
Ended |
|
September 30, |
|
September 30, |
|
|
2019 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2018 |
|
|
|
|
|
|
|
|
|
GAAP-based
gross profit from U.S. products |
$ |
19,853 |
|
|
$ |
16,001 |
|
|
$ |
55,087 |
|
|
$ |
46,230 |
|
Add:
non-cash excess and obsolete charges |
|
2,276 |
|
|
|
744 |
|
|
|
6,451 |
|
|
|
2,016 |
|
Non-GAAP
gross profit from U.S. products |
$ |
22,129 |
|
|
$ |
16,745 |
|
|
$ |
61,538 |
|
|
$ |
48,246 |
|
|
|
|
|
|
|
|
|
GAAP-based
gross margin from U.S. products |
|
70.8 |
% |
|
|
76.2 |
% |
|
|
71.4 |
% |
|
|
76.3 |
% |
Add:
non-cash excess and obsolete charges |
|
8.1 |
% |
|
|
3.5 |
% |
|
|
8.4 |
% |
|
|
3.3 |
% |
Non-GAAP
gross margin from U.S. products |
|
78.9 |
% |
|
|
79.8 |
% |
|
|
79.8 |
% |
|
|
79.6 |
% |
|
|
|
|
|
|
|
|
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Apr 2023 to Apr 2024